Emerging immune targets for the treatment of multiple myeloma

Atif Sohail, Adeela Mushtaq, Ahmad Iftikhar, Zabih Warraich, Sandra E. Kurtin, Pavan Tenneti, Ali McBride, Faiz - Anwer

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

Original languageEnglish (US)
Pages (from-to)265-282
Number of pages18
JournalImmunotherapy
Volume10
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Multiple Myeloma
T-Cell Antigen Receptor
B-Cell Maturation Antigen
Monoclonal Antibodies
Therapeutics
Clinical Trials
T-Lymphocytes
Pharmaceutical Preparations
dacetuzumab
siltuximab
Bevacizumab

Keywords

  • adoptive cell therapy
  • antibodies
  • antibody therapeutics
  • chimeric antigen T cells
  • immunotherapy
  • multiple myeloma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Sohail, A., Mushtaq, A., Iftikhar, A., Warraich, Z., Kurtin, S. E., Tenneti, P., ... Anwer, F. . (2018). Emerging immune targets for the treatment of multiple myeloma. Immunotherapy, 10(4), 265-282. https://doi.org/10.2217/imt-2017-0136

Emerging immune targets for the treatment of multiple myeloma. / Sohail, Atif; Mushtaq, Adeela; Iftikhar, Ahmad; Warraich, Zabih; Kurtin, Sandra E.; Tenneti, Pavan; McBride, Ali; Anwer, Faiz -.

In: Immunotherapy, Vol. 10, No. 4, 01.01.2018, p. 265-282.

Research output: Contribution to journalReview article

Sohail, A, Mushtaq, A, Iftikhar, A, Warraich, Z, Kurtin, SE, Tenneti, P, McBride, A & Anwer, F 2018, 'Emerging immune targets for the treatment of multiple myeloma', Immunotherapy, vol. 10, no. 4, pp. 265-282. https://doi.org/10.2217/imt-2017-0136
Sohail A, Mushtaq A, Iftikhar A, Warraich Z, Kurtin SE, Tenneti P et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018 Jan 1;10(4):265-282. https://doi.org/10.2217/imt-2017-0136
Sohail, Atif ; Mushtaq, Adeela ; Iftikhar, Ahmad ; Warraich, Zabih ; Kurtin, Sandra E. ; Tenneti, Pavan ; McBride, Ali ; Anwer, Faiz -. / Emerging immune targets for the treatment of multiple myeloma. In: Immunotherapy. 2018 ; Vol. 10, No. 4. pp. 265-282.
@article{54d029fdefb64deba39921dd7372381c,
title = "Emerging immune targets for the treatment of multiple myeloma",
abstract = "We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24{\%}. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66{\%}), indatuximab (OR: 78{\%}), isatuximab (OR: 64.5{\%}), pembrolizumab (OR: 60{\%}), bevacizumab (OR: 70{\%}), dacetuzumab (OR: 39{\%}) and lorvotuzumab (OR: 56.4{\%}). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100{\%}. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.",
keywords = "adoptive cell therapy, antibodies, antibody therapeutics, chimeric antigen T cells, immunotherapy, multiple myeloma",
author = "Atif Sohail and Adeela Mushtaq and Ahmad Iftikhar and Zabih Warraich and Kurtin, {Sandra E.} and Pavan Tenneti and Ali McBride and Anwer, {Faiz -}",
year = "2018",
month = "1",
day = "1",
doi = "10.2217/imt-2017-0136",
language = "English (US)",
volume = "10",
pages = "265--282",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Emerging immune targets for the treatment of multiple myeloma

AU - Sohail, Atif

AU - Mushtaq, Adeela

AU - Iftikhar, Ahmad

AU - Warraich, Zabih

AU - Kurtin, Sandra E.

AU - Tenneti, Pavan

AU - McBride, Ali

AU - Anwer, Faiz -

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

AB - We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

KW - adoptive cell therapy

KW - antibodies

KW - antibody therapeutics

KW - chimeric antigen T cells

KW - immunotherapy

KW - multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85041718852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041718852&partnerID=8YFLogxK

U2 - 10.2217/imt-2017-0136

DO - 10.2217/imt-2017-0136

M3 - Review article

C2 - 29421983

AN - SCOPUS:85041718852

VL - 10

SP - 265

EP - 282

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 4

ER -